L’immunothérapie anti-HER 2

In patients with an HER-2 positive cancer, Trastuzumab improves both recurrence-free and overall survival. Generally speaking, Trastuzumab is administered at the same time as chemotherapy, because it has a synergistic effect between the two treatments.

Trastuzumab is mostly administered at the rate of one injection every 3 weeks for one year.

Before and during this treatment, an evaluation of cardiac function should be performed. In case of ejection fraction reduction to less than 50%, Trastuzumab should not be administered.

Other products such as Pertuzumab and TDM-1 have been introduced recently.